LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Hydroxychloroquine use: the potential impact of new ocular screening guidelines.

    Yates, M / Malaiya, R / Stack, J / Galloway, J B

    Eye (London, England)

    2017  Volume 32, Issue 1, Page(s) 161–162

    MeSH term(s) Antirheumatic Agents/therapeutic use ; Humans ; Hydroxychloroquine/therapeutic use ; Practice Guidelines as Topic ; Retinal Diseases/drug therapy
    Chemical Substances Antirheumatic Agents ; Hydroxychloroquine (4QWG6N8QKH)
    Language English
    Publishing date 2017-08-11
    Publishing country England
    Document type Letter
    ZDB-ID 91001-6
    ISSN 1476-5454 ; 0950-222X
    ISSN (online) 1476-5454
    ISSN 0950-222X
    DOI 10.1038/eye.2017.166
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 3010: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 603: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey.

    Mahil, S K / Yates, M / Langan, S M / Yiu, Z Z N / Tsakok, T / Dand, N / Mason, K J / McAteer, H / Meynell, F / Coker, B / Vincent, A / Urmston, D / Vesty, A / Kelly, J / Lancelot, C / Moorhead, L / Bachelez, H / Bruce, I N / Capon, F /
    Contreras, C R / Cope, A P / De La Cruz, C / Di Meglio, P / Gisondi, P / Hyrich, K / Jullien, D / Lambert, J / Marzo-Ortega, H / McInnes, I / Naldi, L / Norton, S / Puig, L / Sengupta, R / Spuls, P / Torres, T / Warren, R B / Waweru, H / Weinman, J / Griffiths, C E M / Barker, J N / Brown, M A / Galloway, J B / Smith, C H

    The British journal of dermatology

    2021  Volume 185, Issue 1, Page(s) 80–90

    Abstract: Background: Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID-19) outcomes compared with patients receiving no systemic ... ...

    Abstract Background: Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID-19) outcomes compared with patients receiving no systemic treatments.
    Objectives: We used international patient survey data to explore the hypothesis that greater risk-mitigating behaviour in those receiving targeted therapies may account, at least in part, for this observation.
    Methods: Online surveys were completed by individuals with psoriasis (globally) or rheumatic and musculoskeletal diseases (RMDs) (UK only) between 4 May and 7 September 2020. We used multiple logistic regression to assess the association between treatment type and risk-mitigating behaviour, adjusting for clinical and demographic characteristics. We characterized international variation in a mixed-effects model.
    Results: Of 3720 participants (2869 psoriasis, 851 RMDs) from 74 countries, 2262 (60·8%) reported the most stringent risk-mitigating behaviour (classified here under the umbrella term 'shielding'). A greater proportion of those receiving targeted therapies (biologics and Janus Kinase inhibitors) reported shielding compared with those receiving no systemic therapy [adjusted odds ratio (OR) 1·63, 95% confidence interval (CI) 1·35-1·97]. The association between targeted therapy and shielding was preserved when standard systemic therapy was used as the reference group (OR 1·39, 95% CI 1·23-1·56). Shielding was associated with established risk factors for severe COVID-19 [male sex (OR 1·14, 95% CI 1·05-1·24), obesity (OR 1·37, 95% CI 1·23-1·54), comorbidity burden (OR 1·43, 95% CI 1·15-1·78)], a primary indication of RMDs (OR 1·37, 95% CI 1·27-1·48) and a positive anxiety or depression screen (OR 1·57, 95% CI 1·36-1·80). Modest differences in the proportion shielding were observed across nations.
    Conclusions: Greater risk-mitigating behaviour among people with IMIDs receiving targeted therapies may contribute to the reported lower risk of adverse COVID-19 outcomes. The behaviour variation across treatment groups, IMIDs and nations reinforces the need for clear evidence-based patient communication on risk-mitigation strategies and may help inform updated public health guidelines as the pandemic continues.
    MeSH term(s) COVID-19 ; Cross-Sectional Studies ; Humans ; Joint Diseases ; Male ; Pandemics ; SARS-CoV-2
    Language English
    Publishing date 2021-03-09
    Publishing country England
    Document type Journal Article
    ZDB-ID 80076-4
    ISSN 1365-2133 ; 0007-0963
    ISSN (online) 1365-2133
    ISSN 0007-0963
    DOI 10.1111/bjd.19755
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui VI Zs.23: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study.

    Mahil, S K / Yates, M / Yiu, Z Z N / Langan, S M / Tsakok, T / Dand, N / Mason, K J / McAteer, H / Meynell, F / Coker, B / Vincent, A / Urmston, D / Vesty, A / Kelly, J / Lancelot, C / Moorhead, L / Bachelez, H / Capon, F / Contreras, C R /
    De La Cruz, C / Di Meglio, P / Gisondi, P / Jullien, D / Lambert, J / Naldi, L / Norton, S / Puig, L / Spuls, P / Torres, T / Warren, R B / Waweru, H / Weinman, J / Brown, M A / Galloway, J B / Griffiths, C M / Barker, J N / Smith, C H

    Journal of the European Academy of Dermatology and Venereology : JEADV

    2021  Volume 35, Issue 10, Page(s) e636–e640

    MeSH term(s) COVID-19 ; Cross-Sectional Studies ; Humans ; Pandemics ; Psoriasis/epidemiology ; SARS-CoV-2
    Language English
    Publishing date 2021-08-19
    Publishing country England
    Document type Letter
    ZDB-ID 1128828-0
    ISSN 1468-3083 ; 0926-9959
    ISSN (online) 1468-3083
    ISSN 0926-9959
    DOI 10.1111/jdv.17450
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3492: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 413: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.

    Galloway, J B / Hyrich, K L / Mercer, L K / Dixon, W G / Ustianowski, A P / Helbert, M / Watson, K D / Lunt, M / Symmons, D P M

    Annals of the rheumatic diseases

    2011  Volume 70, Issue 10, Page(s) 1810–1814

    Abstract: Objectives: To evaluate the risk of septic arthritis (SA) in patients with rheumatoid arthritis (RA) treated with anti-tumour necrosis factor (TNF) therapy.: Methods: Using data from the British Society for Rheumatology Biologics Register, a ... ...

    Abstract Objectives: To evaluate the risk of septic arthritis (SA) in patients with rheumatoid arthritis (RA) treated with anti-tumour necrosis factor (TNF) therapy.
    Methods: Using data from the British Society for Rheumatology Biologics Register, a prospective observational study, the authors compared the risk of SA between 11 881 anti-TNF-treated and 3673 non-biological disease-modifying antirheumatic drug (nbDMARD)-treated patients.
    Results: 199 patients had at least one episode of SA (anti-TNF: 179, nbDMARD: 20). Incidence rates were: anti-TNF 4.2/1000 patient years (pyrs) follow-up (95% CI 3.6 to 4.8), nbDMARD 1.8/1000 pyrs (95% CI 1.1 to 2.7). The adjusted HR for SA in the anti-TNF cohort was 2.3 (95% CI 1.2 to 4.4). The risk did not differ significantly between the three agents: adalimumab, etanercept and infliximab. The risk was highest in the early months of therapy. The patterns of reported organisms differed in the anti-TNF cohort. Prior joint replacement surgery was a risk factor for SA in all patients. The rate of postoperative joint infection (within 90 days of surgery) was 0.7%. This risk was not significantly influenced by anti-TNF therapy.
    Conclusions: Anti-TNF therapy use in RA is associated with a doubling in the risk of SA. Physicians and surgeons assessing the RA patient should be aware of this potentially life-threatening complication.
    MeSH term(s) Adult ; Aged ; Antirheumatic Agents/adverse effects ; Arthritis, Infectious/complications ; Arthritis, Infectious/epidemiology ; Arthritis, Rheumatoid/complications ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/epidemiology ; Epidemiologic Methods ; Female ; Humans ; Immunosuppressive Agents/adverse effects ; Joint Prosthesis/adverse effects ; Male ; Middle Aged ; Opportunistic Infections/complications ; Opportunistic Infections/epidemiology ; Prosthesis-Related Infections/complications ; Prosthesis-Related Infections/epidemiology ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; United Kingdom/epidemiology
    Chemical Substances Antirheumatic Agents ; Immunosuppressive Agents ; Tumor Necrosis Factor-alpha
    Language English
    Publishing date 2011-07-21
    Publishing country England
    Document type Comparative Study ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/ard.2011.152769
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.114: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 167: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Vagotomy and pyloric dilatation in chronic duodenal ulceration.

    Thomson, J D / Galloway, J B

    British medical journal

    1979  Volume 1, Issue 6176, Page(s) 1453–1455

    Abstract: A total of 101 patients suffering from duodenal ulcer underwent truncal vagotomy (TV) combined with pyloric dilatation (PD). They were followed up over six years, and the results were found to compare favourably with those in patients who underwent ... ...

    Abstract A total of 101 patients suffering from duodenal ulcer underwent truncal vagotomy (TV) combined with pyloric dilatation (PD). They were followed up over six years, and the results were found to compare favourably with those in patients who underwent alternative surgical measures. Before any revisionary surgery 79 patients were classified as Visick grades I plus II. The incidence of recurrent ulceration was 4%. Side effects were noticeably less common than in patients in whom a drainage procedure had been performed, and overall results were compared with those reported for groups of patients treated by proximal gastric vagotomy. The combination of TV and PD is commended on account of its simplicity, safety, and effectiveness at a time when medical treatment for duodenal ulcer is becoming more specific and increasingly effective.
    MeSH term(s) Chronic Disease ; Dilatation ; Duodenal Ulcer/surgery ; Follow-Up Studies ; Humans ; Pylorus/surgery ; Recurrence ; Vagotomy/adverse effects
    Language English
    Publishing date 1979-06-02
    Publishing country England
    Document type Comparative Study ; Journal Article
    ZDB-ID 80088-0
    ISSN 0007-1447 ; 0267-0623 ; 0959-8138 ; 0959-8146
    ISSN 0007-1447 ; 0267-0623 ; 0959-8138 ; 0959-8146
    DOI 10.1136/bmj.1.6176.1453
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.10: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Risk mitigating behaviours in people with inflammatory joint and skin disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey

    Mahil, S. K. / Yates, M. / Langan, S. M. / Yiu, Z. Z. / Tsakok, T. / Dand, N. / Mason, K. J. / McAteer, H. / Meynall, F. / Coker, B. / Vincent, A. / Urmston, D. / Vesty, A. / Kelly, J. / Lancelot, C. / Moorhead, L. / Bachelez, H. / Bruce, I. N. / Capon, F. /
    Contreras, C. R. / Cope, A. P. / De La Cruz, C. / Di Meglio, P. / Gisondi, P. / Hyrich, K. / Jullien, D. / Lambert, J. / Waweru, H. / Marzo-Ortega, H. / McInnes, I. / Naldi, L. / Norton, S. / Puig, L. / Spuls, P. / Sengupta, R. / Torres, T. / Warren, R. B. / Weinman, J. / Griffiths, C. E. / Barker, J. N. / Brown, M. A. / Galloway, J. B. / Smith, C. H.

    Abstract: Objectives Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse COVID-19 outcomes compared to patients receiving no systemic treatments. We used international ... ...

    Abstract Objectives Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse COVID-19 outcomes compared to patients receiving no systemic treatments. We used international patient survey data to explore the hypothesis that greater risk-mitigating behaviour in those receiving targeted therapies may account, at least in part, for this observation. Methods Online surveys were completed by individuals with Rheumatic and Musculoskeletal Diseases (RMD) (UK only) or psoriasis (globally) between 4th May and 7th September 2020. We used multiple logistic regression to assess the association between treatment type and risk-mitigating behaviour, adjusting for clinical and demographic characteristics. We characterised international variation in a mixed effects model. Results Of 3,720 participants (2,869 psoriasis, 851 RMD) from 74 countries, 2,262 (60.8%) reported the most stringent risk-mitigating behaviour (classified here under the umbrella term shielding). A greater proportion of those receiving targeted therapies (biologics and JAK inhibitors) reported shielding compared to those receiving no systemic therapy (adjusted odds ratio [OR] 1.63, 95% CI 1.35-1.97) and standard systemic agents (OR 1.39, 95% CI 1.22-1.56). Shielding was associated with established risk factors for severe COVID-19 (male sex [OR 1.14, 95% CI 1.05-1.24], obesity [OR 1.38, 95% CI 1.23-1.54], comorbidity burden [OR 1.43, 95% CI 1.15-1.78]), a primary indication of RMD (OR 1.37, 95% CI 1.27-1.48) and a positive anxiety or depression screen (OR 1.57, 95% CI 1.36-1.80). Modest differences in the proportion shielding were observed across nations. Conclusions Greater risk-mitigating behaviour among people with IMIDs receiving targeted therapies may contribute to the reported lower risk of adverse COVID-19 outcomes. The behaviour variation across treatment groups, IMIDs and nations reinforces the need for clear evidence-based patient communication on risk mitigation strategies and may help inform updated public health guidelines as the pandemic continues.
    Keywords covid19
    Publisher MedRxiv; WHO
    Document type Article ; Online
    DOI 10.1101/2020.11.05.20226662
    Database COVID19

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article: Perforation of the intestine due to muscular violence.

    Galloway, J B / McKirdy, H

    British medical journal

    1966  Volume 2, Issue 5530, Page(s) 1636

    MeSH term(s) Aged ; Humans ; Ileum ; Intestinal Perforation/etiology ; Male ; Muscle, Smooth/injuries ; Muscular Diseases/complications
    Language English
    Publishing date 1966-12-31
    Publishing country England
    Document type Case Reports ; Journal Article
    ZDB-ID 80088-0
    ISSN 0007-1447 ; 0267-0623 ; 0959-8138 ; 0959-8146
    ISSN 0007-1447 ; 0267-0623 ; 0959-8138 ; 0959-8146
    DOI 10.1136/bmj.2.5530.1636
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.10: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top